Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Riviciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 15/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 14/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 12/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 3/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 1.00 |
| ▸ | CDKL5 | O76039 | 2/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 2/20 | 1.00 |
| ▸ | CILK1 | Q9UPZ9 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 1.00 |
| ▸ | DDX42 | Q86XP3 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 13/20 | 0.98 |
| ▸ | CDK2 | P24941 | 12/20 | 0.98 |
| ▸ | CCNB1 | P14635 | 11/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riviciclib SCHEMBL290347 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL663220 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL29387962 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL6119675 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL663219 | 1.00 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL23683025 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL17348307 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL665749 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL31702788 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Riviciclib SCHEMBL291157 | 0.99 | CDK4 (1.00) | CDK4CDK1CDK9GSK3BPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390318-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CDK INHIBITOR AND ID2 ACTIVATOR FOR PREVENTION OR TREATMENT OF BLADDER CANCER | THE ASAN FOUNDATION (KR) | 2024-11-28 | — | — | US | claimed |
| CN-117982498-A | Composition containing protein degradation agent or inhibitor and application thereof | 苏州开拓药业股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| WO-2023059040-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CDK INHIBITOR AND ID2 ACTIVATOR FOR PREVENTION OR TREATMENT OF BLADDER CANCER | 재단법인 아산사회복지재단 | 2023-04-13 | — | — | WO | claimed |
| CN-122094689-A | Combination therapy of diacylglycerol kinase (DGK) alpha inhibitors with other therapies | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | disclosed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025227060-A1 | HETEROCYCLIC INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) IN COMBINATION WITH ADDITIONAL AGENTS FOR USE IN THE TREATMENT OF CANCER | INSILICO MEDICINE IP LIMITED (CN) | 2025-10-30 | — | — | WO | disclosed |
| EP-4568662-A1 | COMPOUNDS FOR TREATING CANCER | Evexta Bio (FR) | 2025-06-18 | — | — | EP | disclosed |
| CN-119997942-A | Compounds for the treatment of cancer | 埃维克斯塔生物公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025068468-A1 | METHODS, SYSTEMS, COMPOSITIONS AND USES FOR IMPROVED PRODUCTION OF VIRAL VECTORS | Sartorius Xell GmbH (DE) | 2025-04-03 | — | — | WO | disclosed |
| EP-4353236-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | OnQuality Pharmaceuticals China Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024033513-A1 | COMPOUNDS FOR TREATING CANCER | DIACCURATE (FR) | 2024-02-15 | — | — | WO | disclosed |
| CN-117529322-A | Compounds and methods for treating chemotherapy-related gastrointestinal side effects | 上海岸阔医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2023243971-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEMYELINATING DISEASE, COMPRISING KINASE INHIBITOR AS ACTIVE INGREDIENT | 고려대학교 산학협력단 | 2023-12-21 | — | — | WO | disclosed |
| WO-2023059040-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CDK INHIBITOR AND ID2 ACTIVATOR FOR PREVENTION OR TREATMENT OF BLADDER CANCER | 재단법인 아산사회복지재단 | 2023-04-13 | — | — | WO | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022258001-A1 | COMPOUND AND METHOD FOR TREATING CHEMOTHERAPY-RELATED GASTROINTESTINAL SIDE EFFECTS | 上海岸阔医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| CN-112915080-B | Application of p276-00 in preparation of medicine for preventing and treating noise-induced hearing loss | 上海交通大学医学院附属第九人民医院 | 2022-03-25 | — | — | CN | disclosed |
| CN-112915080-B | Application of p276-00 in preparation of medicine for preventing and treating noise-induced hearing loss | 上海交通大学医学院附属第九人民医院 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | CDK4 1973/4885CDK1 949/4885CDK9 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.